Beam Therapeutics Inc. 8-K Report: Key Developments on February 25, 2025

Based on the provided section of the financial report, here are the key pieces of information extracted:

Filing Type and Date:

Filing Type: 8-K
Filing Date: February 25, 2025

Company Information:

Company Name: Beam Therapeutics Inc.
State of Incorporation: Delaware (DE)
SEC Central Index Key (CIK): 0001745999
IRS Employer Identification Number (EIN): 81-5238376
Address: 238 Main Street, Cambridge, MA 02142
Phone Number: 857-327-8775

Stock Information:

Common Stock: Par value of $0.01 per share
Stock Ticker: BEAM
Exchange: NASDAQ

Period Covered:

Start Date: February 25, 2025
End Date: February 25, 2025

Insights:

The report is a Form 8-K, which typically indicates a significant event or corporate change that is important to shareholders.
The filing date coincides with the period covered, suggesting that this report may pertain to an event that occurred on that specific date.
Beam Therapeutics Inc. is a publicly traded company on NASDAQ, which may indicate it has undergone important developments relevant to investors or market stakeholders.

This information could be crucial for investors monitoring Beam Therapeutics for any material changes or events that could impact stock price or business operations.